Regeneron Pharmaceuticals (NASDAQ:REGN) Director Huda Zoghbi Sells 800 Shares of Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Huda Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $797.99 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The firm has a fifty day moving average of $668.89 and a 200 day moving average of $713.34. The firm has a market cap of $82.16 billion, a PE ratio of 19.72, a PEG ratio of 1.36 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same period last year, the firm posted $12.81 earnings per share. The company’s revenue was up 16.7% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analyst commentary highlights continued growth from Eylea HD and Dupixent, along with progress in oncology and Regeneron’s broader pipeline. REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
• Positive Sentiment: Goldman Sachs maintained its Buy rating on Regeneron, reinforcing a constructive view of the company’s long-term prospects. Goldman Sachs Keeps Their Buy Rating on Regeneron
• Neutral Sentiment: Directors Huda Y. Zoghbi and Kathryn Guarini each sold shares at approximately $800 under pre-arranged Rule 10b5-1 trading plans. The transactions reduced their holdings by about 32% and 40%, respectively, but the plans lessen the signal that the sales reflect current views of Regeneron’s outlook. Director Sale Filing
• Negative Sentiment: Several law firms publicized a securities class action related to alleged investor harm and claims that Regeneron misled investors about the prospects of its Phase 3 fianlimab-Libtayo trial in advanced melanoma. The trial failure previously caused an approximately $11 billion market-value loss; the legal notices could sustain concern about litigation costs, disclosure practices and the oncology pipeline. The lead-plaintiff deadline is September 14, 2026. Regeneron Class Action Lawsuit Notice

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. WPG Advisers LLC increased its holdings in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares during the last quarter. SHP Wealth Management acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $26,000. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $26,000. Titan Wealth CI Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $29,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on REGN. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. TD Cowen raised their target price on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research report on Thursday, April 23rd. Wells Fargo & Company lifted their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Cantor Fitzgerald boosted their price target on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Finally, Citigroup increased their price objective on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $797.75.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.